Tracking the Trends in the Adoption of Reliever-Only ICS-Formoterol Therapy and SMART.
作者信息
Zaeh Sandra E, Krings James G
机构信息
Division of Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, Conn.
Division of Pulmonary Critical Care Medicine, Washington University School of Medicine, St. Louis, Mo.
出版信息
J Allergy Clin Immunol Pract. 2023 Sep;11(9):2765-2766. doi: 10.1016/j.jaip.2023.05.038. Epub 2023 Sep 6.
Abstract
摘要
相似文献
1
Tracking the Trends in the Adoption of Reliever-Only ICS-Formoterol Therapy and SMART.追踪仅使用缓解药物的吸入性糖皮质激素-福莫特罗疗法及症状驱动治疗（SMART）的应用趋势。
J Allergy Clin Immunol Pract. 2023 Sep;11(9):2765-2766. doi: 10.1016/j.jaip.2023.05.038. Epub 2023 Sep 6.
2
Beginning to Address an Implementation Gap in Asthma: Clinicians' Views of Prescribing Reliever Budesonide-Formoterol Inhalers and SMART in the United States.开始解决哮喘治疗中的实施差距问题：美国临床医生对处方缓解药物布地奈德-福莫特罗吸入剂和 SMART 的看法。
J Allergy Clin Immunol Pract. 2023 Sep;11(9):2767-2777. doi: 10.1016/j.jaip.2023.05.023. Epub 2023 May 26.
3
Protocol for the INFORM ASTHMA Trial: budesonide-formoterol reliever in adults with asthma on maintenance inhaled corticosteroid.INFORM哮喘试验方案：布地奈德-福莫特罗用于接受维持吸入性糖皮质激素治疗的成年哮喘患者的缓解剂
ERJ Open Res. 2025 Jul 7;11(4). doi: 10.1183/23120541.01208-2024. eCollection 2025 Jul.
4
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children.福莫特罗与布地奈德联合用于成人和儿童慢性哮喘的维持和缓解治疗与当前最佳实践（包括吸入性糖皮质激素维持治疗）的对比研究
Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD007313. doi: 10.1002/14651858.CD007313.pub3.
5
A network meta-analysis of the association between patient traits and response to regular dosing with ICS plus short-acting β-agonist reliever or ICS/formoterol reliever only in mild asthma.一项网络荟萃分析，评估患者特征与中重度哮喘患者接受常规ICS+SABA 或 ICS/福莫特罗治疗的反应之间的关系。
Respir Med. 2024 May;226:107610. doi: 10.1016/j.rmed.2024.107610. Epub 2024 Mar 30.
6
Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children.福莫特罗与布地奈德联合用于成人和儿童慢性哮喘的维持和缓解治疗与联合吸入器维持治疗的对比
Cochrane Database Syst Rev. 2013 Dec 16;2013(12):CD009019. doi: 10.1002/14651858.CD009019.pub2.
7
A cost-utility analysis of single maintenance and reliever (SMART) therapy as compared to step 3 fixed-dose therapy in patients aged 12 years or more with uncontrolled asthma.12岁及以上未控制哮喘患者中，单剂量维持和缓解治疗（SMART）与第3步固定剂量治疗的成本-效用分析。
Pediatr Pulmonol. 2025 Jan;60(1):e27328. doi: 10.1002/ppul.27328. Epub 2024 Oct 23.
8
Inhaled Reliever Therapies for Asthma: A Systematic Review and Meta-Analysis.哮喘的吸入缓解疗法：一项系统评价与荟萃分析
JAMA. 2025 Jan 14;333(2):143-152. doi: 10.1001/jama.2024.22700.
9
A network meta-analysis of the association between patient traits and response to regular dosing with ICS/long-acting β-agonist plus short-acting β agonist reliever or maintenance and reliever therapy for asthma.一项关于患者特征与常规剂量 ICS/长效β激动剂加短效β激动剂缓解剂或维持缓解治疗哮喘反应之间关系的网络荟萃分析。
Respir Med. 2023 Nov;218:107377. doi: 10.1016/j.rmed.2023.107377. Epub 2023 Jul 29.
10
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].[支气管哮喘防治指南（2024年版）]
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.
引用本文的文献
1
Can we measure whether asthma guidelines lead to improved care?我们能否衡量哮喘指南是否能带来改善的护理？
NPJ Prim Care Respir Med. 2024 Jun 27;34(1):16. doi: 10.1038/s41533-024-00379-6.
2
Adoption and implementation of maintenance and reliever therapy for adults with moderate-to-severe asthma.成人中重度哮喘维持和缓解治疗的采用和实施。
Ann Allergy Asthma Immunol. 2024 Sep;133(3):318-324. doi: 10.1016/j.anai.2024.06.011. Epub 2024 Jun 17.
本文引用的文献
1
Patterns of Asthma Medication Use in New Zealand After Publication of National Asthma Guidelines.新西兰国家哮喘指南发布后哮喘药物使用模式。
J Allergy Clin Immunol Pract. 2023 Sep;11(9):2757-2764.e5. doi: 10.1016/j.jaip.2023.04.041. Epub 2023 May 11.
2
A Call for the United States to Accelerate the Implementation of Reliever Combination Inhaled Corticosteroid-Formoterol Inhalers in Asthma.呼吁美国加快在哮喘治疗中使用缓解型吸入性糖皮质激素-福莫特罗联合吸入器的实施。
Am J Respir Crit Care Med. 2023 Feb 15;207(4):390-405. doi: 10.1164/rccm.202209-1729PP.
3
Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals.公众保险人群中生物制剂治疗哮喘的使用率较低。
J Allergy Clin Immunol Pract. 2021 Nov;9(11):3969-3976. doi: 10.1016/j.jaip.2021.01.039. Epub 2021 Feb 6.
4
2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.2020 年哮喘管理指南重点更新：国家哮喘教育和预防计划协调委员会专家小组工作组的报告。
J Allergy Clin Immunol. 2020 Dec;146(6):1217-1270. doi: 10.1016/j.jaci.2020.10.003.
5
Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.布地奈德福莫特罗缓解治疗与布地奈德加特布他林维持缓解治疗轻中度哮喘成人患者（PRACTICAL）：一项 52 周、开放标签、多中心、优效性、随机对照试验。
Lancet. 2019 Sep 14;394(10202):919-928. doi: 10.1016/S0140-6736(19)31948-8. Epub 2019 Aug 23.
6
GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents.《2019年全球哮喘防治创议》：哮喘管理的根本性变革：不再建议仅用短效支气管扩张剂治疗成人和青少年哮喘。
Eur Respir J. 2019 Jun 27;53(6). doi: 10.1183/13993003.01046-2019. Print 2019 Jun.
7
Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.按需使用布地奈德-福莫特罗治疗轻度哮喘的对照试验。
N Engl J Med. 2019 May 23;380(21):2020-2030. doi: 10.1056/NEJMoa1901963. Epub 2019 May 19.
8
Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis.吸入性糖皮质激素与长效β受体激动剂联合作为持续性哮喘控制和快速缓解治疗与病情加重及症状控制的关联：一项系统评价和荟萃分析
JAMA. 2018 Apr 10;319(14):1485-1496. doi: 10.1001/jama.2018.2769.
Zotero 插件